Abstract: A method and apparatus for physically separating polypeptide constituents of a sample fluid by (a) providing a sample fluid comprising a mixture of polypeptides of differing physical and/or chemical properties; (b) contacting the fluid with at least two individual polymer matrix units, each polymer matrix unit preferentially accepting a different set of polypeptides on the basis of one or more physical and/or chemical properties; and (c) extracting the set of polypeptides from each polymer matrix unit.

Abstract: A method and apparatus for physically separating polypeptide constituents of a sample fluid by (a) providing a sample fluid comprising a mixture of polypeptides of differing physical and/or chemical properties; (b) contacting the fluid with at least two individual polymer matrix units, each polymer matrix unit preferentially accepting a different set of polypeptides on the basis of one or more physical and/or chemical properties; and (c) extracting the set of polypeptides from each polymer matrix unit.

Abstract: The present invention includes 16-HETE analogs which are agonists and antagonists of 16-HETE. The compositions may be formulated in pharmaceutically acceptable formulations. The invention also includes methods and products for inhibiting neutrophil adhesion and neutrophil aggregation using the 16-HETE agonists. One method of the invention involves the administration of a 16-HETE agonist in combination with a thrombolytic agent to a patient suffering from thromboembolic stroke.

Abstract: A bulge testing system (10) for testing the material properties of a thin film window (14) using a Michelson interferometer (18) that generates an interference pattern (32) having fringes (34) and nodes (36) that move as the thin film window is inflated or deflated. The bulge testing system includes a fringe counting module (82), an analysis module (114) and an output module (88). The fringe counting module allows a user to interactively select from an image of the interference pattern one or more sampling regions (30) in which the user interface will count fringes. The analysis module allows a user to interactively change the location of maxima/minima indicators (116) in the event that noise in the image causes the analysis module to incorrectly determine the locations of the fringes and nodes. The output module automatically calculates material properties and provides test results to an output file and/or a results window (168).

Abstract: A method of curing a photosensitive material (10) having a critical electrical field amplitude at which photoinitiation occurs. The method includes contacting the photosensitive material, e.g., a photoinitiator/monomer resin system, with a substrate (18), such as an optical element, so as to form an interface (20) between the photosensitive material and the substrate. A light beam (12) is directed into the substrate such that the light beam is totally internally reflected from the interface within the substrate so that an evanescent wave is created in the photosensitive material. In order for curing to occur, the electric field amplitude of the evanescent wave at the interface must be at least equal to the critical electric field amplitude of the photosensitive material.

Abstract: A pn junction diode (250) having its metallurgical junction of the oppositely-doped regions (254, 256) coincident with the surface WS of an electrically-doped wafer W and a method of forming such a diode. The method includes preparing (202) the wafer surface prior to placing the wafer into a reaction chamber (14). The preparation of the wafer surface includes UV ozonation (102d) and hydrogen-termination (102e) in a hydrofluoric acid solution. After the wafer surface is prepared, the wafer is inserted into the reaction chamber and heated to a temperature of less than 650° C. Without delay, a pn junction (252) is formed by growing on the wafer surface an epitaxial film layer having a doping opposite the doping of the wafer. The doped film layer is grown (204) by plasma-enhanced chemical vapor deposition while simultaneously introducing dopant atoms into the reaction chamber.

Abstract: A bulge tester (20) for determining residual stresses, and mechanical, thermal and other properties of a thin film (26) of material. The bulge tester includes a chuck (22) that supports the substrate (24) on which the film is deposited by stiction rather than through the use of mounting waxes, adhesives and mechanical clamping. The stiction inducing media (52) may be viscous grease, a flexible sheet of material such as a rubber, an elastomer, both or other materials. Bulge testing performed using the stiction-based chuck involves inducing stiction between the base (42) of the chuck and substrate of at least at least 1 kPascal (0.69 lb/in2), as determined using a corner peel test. Then pressurized fluid is delivered to the film to be tested, and materials properties of the film are determined as a function of pressure of the fluid and deflection of the film.

Abstract: Monoclonal antibodies directed against coagulation factors and their use in inhibiting thrombosis are disclosed.

Abstract: The present invention includes 16-HETE analogs which are agonists and antagonists of 16-HETE. The compositions may be formulated in pharmaceutically acceptable formulations. The invention also includes methods and products for inhibiting neutrophil adhesion and neutrophil aggregation using the 16-HETE agonists. One method of the invention involves the administration of a 16-HETE agonist in combination with a thrombolytic agent to a patient suffering from thromboembolic stroke.

Abstract: A method of preparing mesoporous silica from a reaction mixture comprising a mineral acid such as HCl, an inorganic oxide source such as tetraethoxysilane, a surfactant such as cetyltrimethlyammonium bromide and water. The reaction mixture is mixed, e.g., by stirring or sonication, until sufficiently polymerized that mesostructured silica may be formed by a subsequent heating step, as indicated by the reaction mixture becoming opaque. This mixing is typically performed at room temperature for about 30-70 minutes. Then, the reaction mixture is heated in a pressurized vessel at a time, temperature and pressure sufficient to form mesostructured silica, e.g., at 60 to 230° C. for 15 to 80 minutes. Finally, mesoporous silica is recovered by filtering, drying and calcining in a furnace having a temperature in the range of 400 to 600° C. in air for at least 6 hours.

Abstract: A process of epitaxially growing a Group IV semiconductor film on a surface (WS) of a substrate (W) made of a material comprising one of Si or Ge in a reaction chamber (14) under vacuum. The process includes the steps of heating the substrate to a temperature between 300° C. and 650° C., then introducing into the reaction chamber a first reactant gas containing one of Si and Ge corresponding to the material comprising the substrate while bombarding the surface with energetic ions having a flux ratio of about between 0.5 and 5 eV/adatom. The first reactant gas may be silane and the substrate made of Si, in which case the semiconductor film grown is Si. Alternatively, the first reactant gas may be germane and the substrate made of Ge, in which case the semiconductor film grown is Ge. Likewise, compounds of Si, Ge and C may be formed by introducing reactant gases comprising Si, Ge and C, for example silane, germane and methane, in the appropriate ratios.

Abstract: The present invention provides methods and products for inhibiting neutrophil adhesion and neutrophil aggregation. The invention includes a method for treating a subject to inhibit neutrophil adhesion and neutrophil aggregation by administering 16-hydroxyeicosatetraenoic acid (16-HETE) to the subject. 16-HETE is an arachidonic acid metabolite. The invention also includes a pharmaceutical preparation of 16-HETE. Methods and products are also provided for treating thromboembolic stroke. The method involves the administration of 16-HETE in combination with a thrombolytic agent to a patient suffering from thromboembolic stroke. Preferably, the 16-HETE is 16(R)-HETE and the thrombolytic agent is tPA. The product is a pharmaceutical preparation of 16-HETE and a thrombolytic agent and a pharmaceutically acceptable carrier.

Abstract: This invention describes novel photoactive ribonucleotides that contain photocrosslinking agents placed at specific internal positions within a ribonucleotide. The invention also provides methods for identifying novel, sequence-specific target molecules, using the photoactive ribonucleotides of the invention, as well as improved nucleic acid hybridization analysis methods.

Abstract: Monoclonal antibodies directed against coagulation factors and their use in inhibiting thrombosis are disclosed.

Abstract: Recombinant transferrin, non-glycosylated recombinant transferrin, transferrin half-molecules and mutant transferrins having altered metal-binding or other properties are described. The recombinant transferrin molecules are expressed in functional form by stable eukaryotic cell lines such as baby hamster kidney cells transformed with an expression vector encoding the recombinant molecule. The recombinant transferrins can be used in metal chelation therapy to bind and clear excess toxic metals in patients suffering from metal overloads or as tissue culture medium supplements or replacements.

Abstract: Persons having the Factor V.sup.LEIDEN mutation and a lower than average plasma level of TFPI have been found to be at elevated risk of thrombosis. Prophylactic methods for reducing the risk of thrombosis employ the administration of TFPI to achieve higher levels in the plasma.

Abstract: Methods and products are provided for treating thromboembolic stroke. A method involves the administration of a thienopyridine derivative in combination with a thrombolytic agent to a patient suffering from thromboembolic stroke. Preferably the thienopyridine derivative is ticlopidine and the thrombolytic agent is tPA. The method also involves the administration of a thrombolytic agent to a subject who already has circulating plasma levels of a thienopyridine derivative. The product is a pharmaceutical preparation of a thienopyridine derivative and a thrombolytic agent and a pharmaceutically acceptable carrier.

Abstract: A bis(platinum) complex having the structure: ##STR1## wherein X, Y, Z, X', Y', and Z' are the same or different ligands and are halide, sulphate, phosphate, nitrate, carboxylate, substituted carboxylate, dicarboxylate, substituted dicarboxylate primary or secondary amine, sulfoxide, phosphine, pyridine-type nitrogen and the like; preferably, there is at least one Pt-anion bond on each Pt molecule; and A is a diamine or polyamine.Complexes of trans geometry ?PtX.sub.2 (L)(L')! where at least L is a planar ligand such as pyridine but preferably quinoline and L' may be amine, sulfoxide or substituted sulfoxide and X is a chloride, nitrate or carboxylate.A process for obtaining bis(platinum) complexes where the two platinum coordination spheres may contain different ligands in each sphere and where the geometry of each platinum coordination sphere may be the same or different.

Abstract: A method to block cytolytic activity of CD8 phenotype T cells using an effective amount of a complement-fixing anti CD8 antibody is described. The anti CD8 antibody may be used to treat patients with immunopathologic disorders induced by viruses or (autoimmune diseases) such as multiple sclerosis, viral or post-viral polyneuropathy, viral or post-viral myocarditis, insulitis, encephalomyelitis, myositis, synovitus, and arthritis.

Abstract: Novel trans-platinum IV complexes which contain heterocycle ligands such as quinoline or isoquinoline, anionic ligands such as halide or sulfate, and which optionally may contain ammonia, or a primary or secondary amine are provided. These complexes have application as pharmaceuticals, in particular as anti-tumor agents.